作者: Karim Ben M’Barek , Walter Habeler , Alexandra Plancheron , Mohamed Jarraya , Florian Regent
DOI: 10.1126/SCITRANSLMED.AAI7471
关键词:
摘要: Replacing defective retinal pigment epithelial (RPE) cells with those derived from human embryonic stem (hESCs) or human-induced pluripotent (hiPSCs) is a potential strategy for treating degenerative diseases. Early clinical trials have demonstrated that hESC-derived hiPSC-derived RPE can be delivered safely as suspension to the eye. The next step transplantation of hESC/hiPSC-derived cell sheets are more physiological. We developed tissue-engineered product consisting grown on amniotic membrane biocompatible substrate. established surgical approach engraft this into subretinal space eyes rats photoreceptor loss. show hESC-RPE scaffold resulted in rescue death and improved visual acuity degeneration compared injected suspension. These results suggest produced under good manufacturing practice conditions may useful diseases degeneration.